Controlling the size and morphology of griseofulvin nanoparticles using polymeric stabilizers by evaporation-assisted solvent–antisolvent interaction method
Source abstract
Abstract
Griseofulvin (GF) is a potential drug for cancer therapy. However, its application is limited by its poor water solubility. Ultrafine GF nanoparticles were prepared through evaporation-assisted solvent–antisolvent interaction method for improving its solubility. Acetone was used as the solvent and water was used as the antisolvent. It was observed that particle size could be controlled by varying the concentration of GF in acetone. Average particle size was very low, 16 ± 4 and 28 ± 8 nm, when the concentration of GF was 5 and 25 mM, respectively, in acetone. However, the particle size increased drastically to more than 3 µm, when the concentration was increased to 50 mM. Interestingly, the presence of optimized concentration of polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) as stabilizers in the antisolvent resulted in significant reduction of particle size. Particle size decreased to less than 40 nm in the presence of the polymeric stabilizers, even when the concentration was 50 mM. Field emission scanning electron microscopy, transmission electron microscopy, and atomic force microscopy imaging revealed that the polymeric stabilizers encapsulated very small GF particles and thus stabilized them. The solubility of GF-HPMC, GF-PVP, and the bare GF particles that were prepared from 50 mM solution (micro-GF) was nearly 24, 19, and 11 times, respectively, higher than that of raw-GF. In vitro dissolution studies revealed that almost 100 % of the drug was released in 60 min from GF-PVP and GF-HPMC. Fourier transform infrared spectroscopy did not detect any strong interaction between GF and the stabilizers. X-ray diffraction showed that the prepared GF nanoparticles and the micro-GF were in polymorphic form I. Differential scanning calorimetric studies showed that the crystallinity of the nanoformulated GF was only slightly lower than that of raw-GF. Thus, particle size reduction and the presence of stabilizers led to significant enhancement in solubility and dissolution rate.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Pharmacological Effects of Natural Compounds · Toxin Mechanisms and Immunotoxins · Phytochemistry and biological activities of Ficus species
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Abbas S, Hayat K, Karangwa E, Bashari M, Zhang X (2013) An overview of ultrasound-assisted food-grade nanoemulsions. Food Eng Rev 5:139–15710.1007/s12393-013-9066-3 ↗
2. Beck C, Sievens-Figueroa L, Gärtner K, Jerez-Rozo JI, Romañach RJ, Bilgili E, Davé RN (2013) Effects of stabilizers on particle redispersion and dissolution from polymer strip films containing liquid antisolvent precipitated griseofulvin particles. Powder Technol 236:37–5110.1016/j.powtec.2012.05.047 ↗
3. Bhakay A, Davé R, Bilgili E (2013) Recovery of BCS class II drugs during aqueous redispersion of core–shell type nanocomposite particles produced via fluidized bed coating. Powder Technol 236:221–23410.1016/j.powtec.2011.12.066 ↗
4. Chen H, Khemtong C, Yang X, Chang X, Gao J (2011) Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 16:354–36010.1016/j.drudis.2010.02.009 ↗
5. Cutrignelli A, Trapani A, Lopedota A, Franco M, Mandracchia D, Denora N, Laquintana V, Trapani G (2011) Griseofulvin/carrier blends: application of partial least squares (PLS) regression analysis for estimating the factors affecting the dissolution efficiency. AAPS PharmSciTech 12:1019–103010.1208/s12249-011-9670-6 ↗
6. Dahan A, Miller JM, Amidon GL (2009) Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 11:740–74610.1208/s12248-009-9144-x ↗
7. Dalvi SV, Dave RN (2010) Analysis of nucleation kinetics of poorly water-soluble drugs in presence of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation. Int J Pharm 387:172–17910.1016/j.ijpharm.2009.12.026 ↗
8. Desai PP, Date AA, Patravale VB (2012) Overcoming poor oral bioavailability using nanoparticle formulations—opportunities and limitations. Drug Discov Today: Technol 9:e87–e9510.1016/j.ddtec.2011.12.001 ↗
9. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P (2008) Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm 70:109–11510.1016/j.ejpb.2008.04.001 ↗
10. Dou H, Kim K-H, Lee B-C, Choe J, Kim H-S, Lee S (2013) Preparation and characterization of cyclo-1,3,5-trimethylene-2,4,6-trinitramine (RDX) powder: comparison of microscopy, dynamic light scattering and field-flow fractionation for size characterization. Powder Technol 235:814–82210.1016/j.powtec.2012.11.042 ↗
11. El-Nakeeb MA, McLellan W, Lampen J (1965) Antibiotic action of griseofulvin on dermatophytes. J Bacteriol 89:557–56310.1128/JB.89.3.557-563.1965 ↗
12. Hu J, Ng WK, Dong Y, Shen S, Tan RB (2011) Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying. Int J Pharm 404:198–20410.1016/j.ijpharm.2010.10.055 ↗
13. Jinno J-I, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T (2008) In vitro–in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release 130:29–3710.1016/j.jconrel.2008.05.013 ↗
14. Kasai H, Murakami T, Ikuta Y, Koseki Y, Baba K, Oikawa H, Nakanishi H, Okada M, Shoji M, Ueda M (2012) Creation of pure nanodrugs and their anticancer properties. Angew Chem 124:10461–1046410.1002/ange.201204596 ↗
15. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85–9610.1021/mp034006h ↗
16. Kesisoglou F, Panmai S, Wu Y (2007) Nanosizing—oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631–64410.1016/j.addr.2007.05.003 ↗
17. Kipp J (2004) The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284:109–12210.1016/j.ijpharm.2004.07.019 ↗
18. Kumar S, Randhawa JK (2013) High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater Sci Eng 33(4):1842–185210.1016/j.msec.2013.01.037 ↗
19. Kumar R, Siril PF (2014) Ultrafine carbamazepine nanoparticles with enhanced water solubility and rate of dissolution. RSC Adv 4:48101–4810810.1039/C4RA08495K ↗
20. Kumar R, Siril PF, Soni P (2014) Preparation of nano-RDX by evaporation assisted solvent–antisolvent interaction. Propellants Explos Pyrotech 39:383–38910.1002/prep.201300104 ↗
21. Kumar R, Siril PF, Soni P (2015) Optimized synthesis of HMX nanoparticles using antisolvent precipitation method. J Energ Mater 33(4):277–28710.1080/07370652.2014.988774 ↗
22. Mahieu A, Willart JF, Dudognon E, Eddleston MD, Jones W, Danède F, Descamps M (2013) On the polymorphism of griseofulvin: identification of two additional polymorphs. J Pharm Sci 102:462–46810.1002/jps.23349 ↗
23. Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113–12010.1016/S0928-0987(02)00251-8 ↗
24. Midoux N, Hošek P, Pailleres L, Authelin J (1999) Micronization of pharmaceutical substances in a spiral jet mill. Powder Technol 104:113–12010.1016/S0032-5910(99)00052-2 ↗
25. Mijatovic D, Eijkel J, Van Den Berg A (2005) Technologies for nanofluidic systems: top-down vs. bottom-up—a review. Lab Chip 5:492–50010.1039/b416951d ↗
26. Nykamp G, Carstensen U, Müller B (2002) Jet milling—a new technique for microparticle preparation. Int J Pharm 242:79–8610.1016/S0378-5173(02)00150-3 ↗
27. Panda D, Rathinasamy K, Santra MK, Wilson L (2005) Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc Natl Acad Sci USA 102:9878–988310.1073/pnas.0501821102 ↗
28. Pongpeerapat A, Itoh K, Tozuka Y, Moribe K, Oguchi T, Yamamoto K (2004) Formation and stability of drug nanoparticles obtained from drug/PVP/SDS ternary ground mixture. J Drug Deliv Sci Technol 14:441–44710.1016/S1773-2247(04)50082-5 ↗
29. Schultz S, Wagner G, Urban K, Ulrich J (2004) High-pressure homogenization as a process for emulsion formation. Chem Eng Technol 27:361–36810.1002/ceat.200406111 ↗
30. Sinha B, Müller RH, Möschwitzer JP (2013) Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm 453:126–14110.1016/j.ijpharm.2013.01.019 ↗
31. Song X, Zhaoc Y, Hou S, Xu F, Zhao R, He J, Cai Z, Lia Y, Chen Q (2008) Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 69(2):445–45310.1016/j.ejpb.2008.01.013 ↗
32. Sulzberger M, Baer R (1959) Griseofulvin: an oral antibiotic for the treatment of many common fungous infections of the skin, hair and nails. Excerpta Med (Dermatol) 13:145
33. Thakur R, Gupta RB (2006) Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. Int J Pharm 308:190–19910.1016/j.ijpharm.2005.11.005 ↗
34. Thorat AA, Dalvi SV (2012) Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: recent developments and future perspective. Chem Eng J 181:1–3410.1016/j.cej.2011.12.044 ↗
35. Trotta M, Gallarate M, Carlotti ME, Morel S (2003) Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int J Pharm 254:235–24210.1016/S0378-5173(03)00029-2 ↗
36. Vasanthavada M, Tong W-QT, Joshi Y, Kislalioglu MS (2005) Phase behavior of amorphous molecular dispersions II: role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440–44810.1007/s11095-004-1882-y ↗
37. Verma S, Gokhale R, Burgess DJ (2009) A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 380:216–22210.1016/j.ijpharm.2009.07.005 ↗
38. Wang YJ, Jeng JH, Chen RJ, Chen LC, Liang YC, Lin CH, Chen CH, Chu JS, Ho WL, Ho YS (2002) Ketoconazole potentiates the antitumor effects of nocodazole: in vivo therapy for human tumor xenografts in nude mice. Mol Carcinog 34:199–21010.1002/mc.10066 ↗
39. Yuan Y, Gao Y, Zhao J, Mao L (2008) Characterization and stability evaluation of β-carotene nanoemulsions prepared by high pressure homogenization under various emulsifying conditions. Food Res Int 41:61–6810.1016/j.foodres.2007.09.006 ↗